Please check your internet connection and try again.
## TUSSQ
This query appears to be malformed or incomplete, preventing a precise identification of the drug or formulation. Assuming "TUSSQ" refers to **Tussionex Pennkinetic** (hydrocodone polistirex and chlorpheniramine polistirex), the following information is provided. If a different product was intended, please resubmit the query with the correct drug name.
### Overview
Tussionex Pennkinetic is a combination cough suppressant and antihistamine product. The polistirex formulation provides extended-release properties.
### Primary Indications
* Relief of cough.
### Adult Dosing
* **Recommended dose:** 5 mL to 10 mL every 12 hours.
* **Maximum dose:** 10 mL every 12 hours.
### Pediatric Dosing
* **Children 6 to 12 years:** 5 mL every 12 hours.
* **Children younger than 6 years:** Safety and efficacy have not been established. Use is not recommended.
### Dose Adjustments
* **Hepatic Impairment:** No specific guidelines available; use with caution and consider reduced dosage due to potential for impaired metabolism of hydrocodone.
* **Renal Impairment:** No specific guidelines available; use with caution and consider reduced dosage.
### Contraindications
* Hypersensitivity to hydrocodone or chlorpheniramine.
* Concurrent use with MAO inhibitors or within 14 days of their discontinuation.
* Significant respiratory depression.
* Acute or severe asthma or other conditions where the central nervous system depressant effect of hydrocodone could be detrimental.
* Gastrointestinal obstruction, including paralytic ileus.
### Adverse Effects
* **Common:** Drowsiness, dizziness, dry mouth, nausea, constipation, blurred vision, confusion.
* **Serious:** Respiratory depression, CNS depression, dependence, abuse, addiction, paradoxical excitation, seizures, severe allergic reactions.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, benzodiazepines, opioids, sedatives):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **MAO Inhibitors:** Potentially exaggerated and prolonged effects of hydrocodone, leading to hypertensive crisis or other severe adverse reactions.
* **Anticholinergic Drugs:** Increased risk of anticholinergic side effects (e.g., urinary retention, severe constipation, ileus).
* **CYP3A4 Inhibitors/Inducers:** May alter hydrocodone metabolism, potentially increasing or decreasing its effects.
### Monitoring
* Assess for relief of cough symptoms.
* Monitor for signs of CNS depression (sedation, dizziness) and respiratory depression.
* Evaluate for signs of constipation and implement preventive measures if necessary.
* Monitor for potential for abuse, dependence, or addiction.
### Clinical Pearls
* The extended-release formulation should not be crushed or chewed.
* Due to the potential for respiratory depression, use the lowest effective dose for the shortest duration necessary.
* Advise patients to avoid alcohol and other CNS depressants.
* Hydrocodone has a potential for abuse and addiction; counsel patients accordingly.
* Antihistamines can cause drowsiness; advise caution when operating machinery or driving.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and professional resources before making clinical decisions. Dosing and indications may vary based on local protocols and individual patient factors.
